ID20283A - Preparat yang mempunyai kemampuan daya tahan in vivo yang ditingkatkan - Google Patents

Preparat yang mempunyai kemampuan daya tahan in vivo yang ditingkatkan

Info

Publication number
ID20283A
ID20283A IDP980708A ID980708A ID20283A ID 20283 A ID20283 A ID 20283A ID P980708 A IDP980708 A ID P980708A ID 980708 A ID980708 A ID 980708A ID 20283 A ID20283 A ID 20283A
Authority
ID
Indonesia
Prior art keywords
preparats
improved capabilities
vivo improved
vivo
capabilities
Prior art date
Application number
IDP980708A
Other languages
English (en)
Indonesian (id)
Inventor
Klaus Dr Bosslet
Jorg Dr Czech
Manfred Dr Gerken
Rainer Dr Straub
Matthias Dr Blumrich
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of ID20283A publication Critical patent/ID20283A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IDP980708A 1997-05-15 1998-05-13 Preparat yang mempunyai kemampuan daya tahan in vivo yang ditingkatkan ID20283A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19720312A DE19720312A1 (de) 1997-05-15 1997-05-15 Zubereitung mit erhöhter in vivo Verträglichkeit

Publications (1)

Publication Number Publication Date
ID20283A true ID20283A (id) 1998-11-19

Family

ID=7829495

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP980708A ID20283A (id) 1997-05-15 1998-05-13 Preparat yang mempunyai kemampuan daya tahan in vivo yang ditingkatkan

Country Status (17)

Country Link
US (1) US6020315A (fr)
EP (1) EP0879605B1 (fr)
JP (1) JP4367798B2 (fr)
KR (1) KR100547923B1 (fr)
CN (1) CN1188134C (fr)
AR (1) AR012694A1 (fr)
AT (1) ATE333899T1 (fr)
AU (1) AU740694B2 (fr)
BR (1) BR9801632A (fr)
CA (1) CA2237450A1 (fr)
CZ (1) CZ149398A3 (fr)
DE (2) DE19720312A1 (fr)
HU (1) HUP9801087A3 (fr)
ID (1) ID20283A (fr)
PL (1) PL193478B1 (fr)
RU (1) RU2234322C2 (fr)
TR (1) TR199800848A3 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2213700C (fr) 1995-02-28 2002-04-02 Hoechst Marion Roussel, Inc. Composition pharmaceutique pour composes de piperidinoalcanol
DE59609305D1 (de) 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
EP0941227B2 (fr) 1996-11-18 2009-10-14 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilone d, mode de preparation et application comme agent cytostatique et phytosanitaire
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
CZ295461B6 (cs) * 1997-08-26 2005-08-17 Aventis Pharmaceuticals Inc. Farmaceutický prostředek ve formě dvouvrstvé tablety
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
HUP0200076A3 (en) 1999-02-22 2003-01-28 Bristol Myers Squibb Co C-21 modified epothilones, process for their preparation, pharmaceutical compositions containing them
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
ES2246234T3 (es) 1999-05-04 2006-02-16 Strakan International Limited Glicosidos de androgenos y actividad androgenica de los mismos.
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
GB2355007A (en) * 1999-10-08 2001-04-11 Michael Francis Holick Tamoxifen analogue glycosides and use thereof
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
CA2307278A1 (fr) * 2000-04-28 2001-10-28 University Of British Columbia Utilisation d'acides salicyliques substitues comportant un heterocycle azote pour l'inhibition de l'assimilation cellulaire de la cystine
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
EP1333811A4 (fr) * 2000-10-16 2004-03-03 Neopharm Inc Preparation liposomales a base de mitoxantrone
WO2002062338A1 (fr) 2001-01-25 2002-08-15 Bristol-Myers Squibb Company Formulations parenterales contenant des analogues d'epothilone
BRPI0206509B8 (pt) 2001-01-25 2021-05-25 R Pharm Us Operating Llc processo para formular, para administração parenteral, um análogo de epotilona, preparação farmacêutica, processo para formar uma composição farmacêutica para administração parental, composição farmacêutica e uso de um análogo de epotilona na preparação de uma composição farmacêutica para o tratamento de câncer
WO2002058699A1 (fr) * 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Formes pharmaceutiques d'epothilones pour administration orale
HUP0303175A2 (hu) 2001-02-20 2003-12-29 Bristol-Myers Squibb Co. Epotilonszármazékok alkalmazása makacs tumorok kezelésére alkalmas gyógyszerkészítmény előállítására
EP1368030A1 (fr) 2001-02-20 2003-12-10 Bristol-Myers Squibb Company Derives d'epothilone destines au traitement de tumeurs refractaires
CA2440555A1 (fr) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combinaison d'analogues d'epothilones et d'agents chimiotherapeutiques servant au traitement de maladies proliferatives
EP1392664A4 (fr) 2001-06-01 2005-01-26 Bristol Myers Squibb Co Derives d'epothilone
US7345023B2 (en) * 2001-08-14 2008-03-18 Valderm Aps Treatment of hyperproliferative conditions of body surfaces
US20030194421A1 (en) * 2001-12-28 2003-10-16 Angiotech Pharmaceuticals, Inc. Treatment of uveitis
WO2003077903A1 (fr) 2002-03-12 2003-09-25 Bristol-Myers Squibb Company Derives c12-cyano epothilone
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
WO2003105828A1 (fr) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combinaison d'analogues d'epothilone et agents chimiotherapeutiques utiles dans le traitement des maladies proliferatives
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
MXPA05002113A (es) 2002-08-23 2005-06-03 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios para ellas, analogos y usos de los mismos.
ES2439995T3 (es) 2002-09-23 2014-01-27 Bristol-Myers Squibb Company Procedimientos de preparación, aislamiento y purificación de epotilona B
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
EP2336141B1 (fr) 2005-06-29 2016-03-30 Threshold Pharmaceuticals, Inc. Prodrogues d'alkylateur de phosphoramidate
US8414526B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US9737640B2 (en) * 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8552048B2 (en) * 2006-12-26 2013-10-08 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs for the treatment of cancer
US20090118031A1 (en) * 2007-11-01 2009-05-07 Qualizza Gregory K Shaft Structure with Configurable Bending Profile
WO2013026453A1 (fr) * 2011-08-22 2013-02-28 Valderm Aps Traitement de troubles inflammatoires avec des anthracyclines
GB201414806D0 (en) * 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
EP0647450A1 (fr) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Prodrogues améliorées pour activation médiée par enzyme
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
DK0751144T3 (da) * 1995-06-27 2004-12-27 Pharmachemie Bv Nye antracyclin-pro-drugs, fremgangsmåde til fremstilling deraf samt antitumorsammensætninger og et komponentkit indeholdende disse pro-drugs
DK0795334T3 (da) * 1996-03-12 2006-06-06 Sanofi Aventis Deutschland Nye prodrugs til behandling af tumorer og betændelsessygdomme

Also Published As

Publication number Publication date
RU2234322C2 (ru) 2004-08-20
US6020315A (en) 2000-02-01
HU9801087D0 (en) 1998-07-28
ATE333899T1 (de) 2006-08-15
EP0879605A3 (fr) 1998-12-02
TR199800848A2 (xx) 1998-12-21
KR19980087239A (ko) 1998-12-05
AU6600598A (en) 1998-11-19
HUP9801087A3 (en) 1999-05-28
EP0879605A2 (fr) 1998-11-25
BR9801632A (pt) 1999-06-29
DE19720312A1 (de) 1998-11-19
KR100547923B1 (ko) 2006-04-12
PL193478B1 (pl) 2007-02-28
JPH1129497A (ja) 1999-02-02
AU740694B2 (en) 2001-11-15
JP4367798B2 (ja) 2009-11-18
AR012694A1 (es) 2000-11-08
PL326336A1 (en) 1998-11-23
HUP9801087A2 (hu) 1998-12-28
CZ149398A3 (cs) 1998-12-16
EP0879605B1 (fr) 2006-07-26
CA2237450A1 (fr) 1998-11-15
CN1188134C (zh) 2005-02-09
TR199800848A3 (tr) 1998-12-21
CN1199613A (zh) 1998-11-25
DE59813653D1 (de) 2006-09-07

Similar Documents

Publication Publication Date Title
ID20283A (id) Preparat yang mempunyai kemampuan daya tahan in vivo yang ditingkatkan
ID28110A (id) Surfaktan alkilbenzenasulfonat yang disempurnakan
DE69833739D1 (de) Kosmetisches Präparat
NO20001612D0 (no) Oralt preparat
ATE348163T1 (de) Thrombopoietin substitute
DE69926816D1 (de) Dental-Verbundwerkstoff
ID25787A (id) Penutup dengan bagian sekat yang diperluas
FR2778085B1 (fr) Implant squelettique
DE69942571D1 (de) Lagerungsbeständige polymerisierbare Zusammensetzung
TW412955U (en) Hair pin
DE59906423D1 (de) Mascara-Einheit
ID16956A (id) Komposisi antijamur dengan ketersediaan hayati yang tertingkatkan
NO20010154L (no) Brønnhulls-strekksvivelovergang
DE59812004D1 (de) Färbemittel
GB9904233D0 (en) Super passwords
NO20011313D0 (no) Nytt preparat
DE29812754U1 (de) Haarwuchsmittel
EE200000288A (et) Hing
NO20011312D0 (no) Nytt preparat
DE29715245U1 (de) Zusammensetzbare Formliege
DE29722695U1 (de) Kanne
FI974624A0 (fi) Tudelad wobbler
DE29802843U1 (de) Reibevorrichtung
DE69731970D1 (de) In vivo rekombination
KR970050853U (ko) 사찰용 위패대